Hard to argue against our walking, talking, breathing miracle patient #11 presenting at 9a. Should get everyone primed for the CEO at noon. Not to mention what seems to be a good safety profile for a high unmet need. Hoping for the ACAD treatment from the FDA, but would settle for any positive FDA trial involvement.
The one thing i haven't read or heard much about, but was in the CEO presentation linked a week back, is that the trial in China is actually a p1, p2, p3 trail all in one. If successful they would be marketable in China. Is that correct?